DK2580210T5 - Østrogenreceptormodulatorer og anvendelser deraf - Google Patents
Østrogenreceptormodulatorer og anvendelser deraf Download PDFInfo
- Publication number
- DK2580210T5 DK2580210T5 DK11793115.4T DK11793115T DK2580210T5 DK 2580210 T5 DK2580210 T5 DK 2580210T5 DK 11793115 T DK11793115 T DK 11793115T DK 2580210 T5 DK2580210 T5 DK 2580210T5
- Authority
- DK
- Denmark
- Prior art keywords
- substituted
- unsubstituted
- phenyl
- methyl
- methylpyrrolidin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
Claims (16)
1. Forbindelse af formel (VI), eller et farmaceutisk acceptabelt salt, eller solvat deraf:
Formel (VI) hvor, R1 er H, F, Ci-C4alkyl, eller Ci-C4fluoralkyl; R3 er H, halogen, Ci-C4alkyl, C3-C6cykloalkyl, eller Ci-C4fluoralkyl; hvert R4 er uafhængigt valgt fra H, halogen, -CN, -OH, -OR9, -SR9, -S(=0)R10, -S(=0)2R10, -C(=0)R10, -C(=0)0H, -C(=0)0R10, -C(=0)NHR10, -C(=O)N(R10)2, substitueret eller ikke-substitueret Ci-C6alkyl, substitueret eller ikke-substitueret Ci-C6fluoralkyl, substitueret eller ikke-substitueret Ci-C6fluoralkoxy, substitueret eller ikke-substitueret Ci-C6alkoxy, og substitueret eller ikke-substitueret Ci-C6heteroalkyl; hvert R5 er uafhængigt valgt fra H, halogen, -CN, -OH, -OR9, -SR9, -S(=0)R10, -S(=0)2R10, substitueret eller ikke-substitueret Ci-Cealkyl, substitueret eller ikke-substitueret Ci-C6fluoralkyl, substitueret eller ikke-substitueret Ci-C6fluoralkoxy, substitueret eller ikke-substitueret Ci-Cealkoxy, og substitueret eller ikke-substitueret Ci-C6heteroalkyl; hvert R6 er uafhængigt valgt fra H, halogen, -CN, -OH, -OR9, -SR9, -S(=0)R10, -S(=0)2R10, substitueret eller ikke-substitueret Ci-Cealkyl, substitueret eller ikke-substitueret Ci-C6fluoralkyl, substitueret eller ikke-substitueret Ci-C6fluoralkoxy, substitueret eller ikke-substitueret Ci-Cealkoxy, og substitueret eller ikke-substitueret Ci-C6heteroalkyl;
er azetidinyl eller pyrrol id inyl; R7 er H eller Ci-C4alkyl; hvert R8 er uafhængigt valgt fra F, Cl, -CN, -OH, -OR9, -SR9, -S(=0)R10, -S(=0)2R10, substitueret eller ikke-substitueret Ci-C6alkyl, substitueret eller ikke-substitueret Ci-C6fluoralkyl, substitueret eller ikke-substitueret Ci-Cefluoralkoxy, substitueret eller ikke-substitueret Ci-C6alkoxy, og substitueret eller ikke-substitueret Ci-C6heteroalkyl; eller 1 R8 taget sammen med R1 sammen med de mellemliggende atomer forbinder R8 til R1 for at danne en 5-, 6-, eller 7-leddet ring; hvert R9 er uafhængigt valgt fra H, -C(=0)R10, -C(=0)0R10, -C(=0)NHR10, substitueret eller ikke-substitueret Ci-C6alkyl, substitueret eller ikke-substitueret Ci-C6heteroalkyl, substitueret eller ikke-substitueret Ci-Cefluoralkyl, substitueret eller ikke-substitueret C3-Ciocykloalkyl, substitueret eller ikke-substitueret C2-Cioheterocykloalkyl, substitueret eller ikke-substitueret aryl, substitueret eller ikke-substitueret heteroaryl, -Ci-C2alkylen-(substitueret eller ikke-substitueret C3-Ciocykloalkyl), -Ci-C2alkylen-(substitueret eller ikke-substitueret C2-Cioheterocykloalkyl), -Ci-C2alkylen-(substitueret eller ikke-substitueret aryl), og -Ci-C2alkylen-(substitueret eller ikke-substitueret heteroaryl); eller hvert R10 er uafhængigt valgt fra substitueret eller ikke-substitueret Ci-Cealkyl, substitueret eller ikke-substitueret Ci-C6heteroalkyl, substitueret eller ikke-substitueret Ci-C6fluoralkyl, substitueret eller ikke-substitueret C3-Ciocykloalkyl, substitueret eller ikke-substitueret C2-Cioheterocykloalkyl, substitueret eller ikke-substitueret aryl, substitueret eller ikke-substitueret heteroaryl, -Ci-C2alkylen-(substitueret eller ikke-substitueret C3-Ciocykloalkyl), -Ci-C2alkylen-(substitueret eller ikke-substitueret C2-Cioheterocykloalkyl), -Ci-C2alkylen-(substitueret eller ikke-substitueret aryl), og -Ci-C2alkylen-(substitueret eller ikke-substitueret heteroaryl); Y er -Ο-, -S-, eller -NR11-; R11 er H, -C(=0)R10, substitueret eller ikke-substitueret Ci-C6alkyl, substitueret eller ikke-substitueret Ci-C6fluoralkyl, eller substitueret eller ikke-substitueret Ci-C6heteroalkyl; X er -O-, -S-, -CH2-, -NH- eller -N(Ci-C6alkyl)-; m er 0, 1, 2, 3 eller 4; n er 0, 1, 2, eller 3; p er 0, 1, 2, 3 eller 4; t er 1, 2, 3 eller 4.
2. Forbindelsen ifølge krav 1, eller et farmaceutisk acceptabelt salt, eller solvat deraf, hvor: R1 er H eller Ci-C4alkyl; R3 er Ci-C4alkyl eller Ci-C4fluoralkyl; hvert R4 er uafhængigt valgt fra H, halogen, -CN, -OH, -OR9, -SR9, -S(=0)R10, -S(=0)2R10, Ci-C4alkyl, Ci-C4fluoralkyl, Ci-C4fluoralkoxy, Ci-C4alkoxy, og Ci-C4heteroalkyl; hvert R5 er uafhængigt valgt fra H, F, Cl, -OH, -CH3, -CF3, -OCF3 og -OCH3; hvert R6 er uafhængigt valgt fra H, F, Cl, -OH, -CH3, -CF3, -OCF3 og -OCH3; R7 er H; hvert R8 er uafhængigt valgt fra F, Cl, -OH, Ci-C4alkyl, Ci-C4fluoralkyl, Ci-C4fluoralkoxy, Ci-C4alkoxy, og Ci-C4heteroalkyl; Y er -O- eller -S-; X er -O-, -S-, -CH2-, -NH- eller -N(CH3)-; p er 0, 1, eller 2.
3. Forbindelsen ifølge krav 1 eller krav 2, eller et farmaceutisk acceptabelt salt, eller solvat deraf, hvor:
4. Forbindelsen ifølge et hvilket som helst af kravene 1-3, eller et farmaceutisk acceptabelt salt, eller solvat deraf, hvor forbindelsen af formel (VI) har strukturen af formel (VIII):
Formel (VIII)
5. Forbindelsen ifølge et hvilket som helst af kravene 1-3, eller et farmaceutisk acceptabelt salt, eller solvat deraf, hvor forbindelsen af formel (VI) har strukturen af formel (IX):
Formel (IX)
6. Forbindelsen ifølge krav 1 eller krav 2, eller et farmaceutisk acceptabelt salt, eller solvat deraf, hvor forbindelsen af formel (VI) har strukturen af formel (X):
hvert R8 er uafhængigt valgt fra F, Cl, -OH, -CH3, -CH2CH3, -CH(CH3)2, -CF3, -CH2CF3, -OCFs, -OCH2CF3, -OCHs, -OCH2CH3, -CH2OCH3, -CH2OCH2CH3, og -CH2OH.
7. Forbindelsen ifølge et hvilket som helst af kravene 1-6, eller et farmaceutisk acceptabelt salt, eller solvat deraf, hvor: R1 er H eller -CH3; R3 er -CH3 eller -CF3; R9 er H; X er -O-.
8. Forbindelsen ifølge et hvilket som helst af kravene 1-5, eller et farmaceutisk acceptabelt salt, eller solvat deraf, hvor:
9. Forbindelse ifølge krav 1, der er: 3-(3-Hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-l- yl)propoxy)phenyl)-2H-chromen-6-ol; (S)-3-(3-Hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-l- yl)propoxy)phenyl)-2H-chromen-6-ol (R)-3-(3-Hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-l- yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(3-Hydroxyphenyl)-4-methyl-2-(4-(2-((R)-3-methylpyrrolidin-l- yl)ethoxy)phenyl)-2H-chromen-6-ol; 3-(3-Hydroxyphenyl)-4-methyl-2-(4-((R)-2-((R)-3-methylpyrrolidin-l- yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(3-Hydroxyphenyl)-4-methyl-2-(4-(2-((S)-3-methylpyrrolidin-l- yl)ethoxy)phenyl)-2H-chromen-6-ol; 3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((S)-3-methylpyrrolidin-l- yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(3-hydroxyphenyl)-4-methyl-2-(4-((R)-2-((S)-3-methylpyrrolidin-l- yl)propoxy)phenyl)-2H-chromen-6-ol; 2-(4-((S)-2-(3,3-Dimethylpyrrolidin-l-yl)propoxy)phenyl)-3-(3- hydroxyphenyl)-4-methyl-2H-chromen-6-ol; 2- (4-(2-(3,3-Dimethylpyrrolid in-l-yl)ethoxy)phenyl)-3-(3-hydroxyphenyl)- 4-methyl-2H-chromen-6-ol; 3- (3-Hydroxyphenyl)-4-methyl-2-(4-(2-((R)-2-methylpyrrolidin-l-yl)ethoxy)phenyl)-2H-chromen-6-ol; 3-(3-Hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-2-methylpyrrolidin-l- yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(3-Hydroxyphenyl)-4-methyl-2-(4-((S)-2-((S)-2-methylpyrrolidin-l- yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(3-Hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-l- yl)propoxy)phenyl)-2H-chromen-7-ol; 3- (4-Hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-l-yl)propoxy)phenyl)-2H-chromen-7-ol;
4- Methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-l-yl)propoxy)phenyl)-3-phenyl-2H-chromen-6-ol; 3-(4-Fluorphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-l- yl)propoxy)phenyl)-2H-chromen-6-ol; (S)-3-(4-Fluorphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-l- yl)propoxy)phenyl)-2H-chromen-6-ol; (R)-3-(4-Fluorphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-l- yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(4-Hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-l- yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(3-Fluorphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-l- yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(3-Fluor-4-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3- methylpyrrolidin-l-yl)propoxy)phenyl)-2H-chromen-6-ol; 2- (2-Fluor-4-((S)-2-((R)-3-methylpyrrolidin-l-yl)propoxy)phenyl)-3-(3-hydroxyphenyl)-4-methyl-2H-chromen-6-ol; 3- (3-Hydroxy-4-methylphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-l-yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(3-Hydroxy-2-methylphenyl)-4-methyl-2-(4-((S)-2-((R)-3- methylpyrrolidin-l-yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(4-Hydroxy-2-methylphenyl)-4-methyl-2-(4-((S)-2-((R)-3- methylpyrrolidin-l-yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(4-Hydroxy-3-methylphenyl)-4-methyl-2-(4-((S)-2-((R)-3- methylpyrrolidin-l-yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(3-Fluor-5-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3- methylpyrrolidin-l-yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(4-Chlorphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-l- yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(2-Fluor-4-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3- methylpyrrolidin-l-yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(3,4-Difluorphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-l- yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(3,5-Difluor-4-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3- methylpyrrolidin-l-yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(2,4-Difluor-3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3- methylpyrrolidin-l-yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(3,4-Difluor-5-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3- methylpyrrolidin-l-yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(2-Chlor-4-Fluorphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-l- yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(2,4-Difluorphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrc>lidin-l- yl)propoxy)phenyl)-2H-chromen-6-ol; 3- (4-Bromphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-l-yl)propoxy)phenyl)-2H-chromen-6-ol;
4- Methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-l-yl)propoxy)phenyl)-3-(o-tolyl)-2H-chromen-6-ol; 3-(4-Fluor-3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3- methylpyrrolidin-l-yl)propoxy)phenyl)-2H-chromen-6-ol; 3- (4-Ethynylphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-l-yl)propoxy)phenyl)-2H-chromen-6-ol;
4- Methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-l-yl)propoxy)phenyl)-3-(4-(methylsulfonyl)phenyl)-2H-chromen-6-ol; 3-(2-Fluor-3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3- methylpyrrolidin-l-yl)propoxy)phenyl)-2H-chromen-6-ol;
5- Fluor-3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-l-yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(2-Fluor-5-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3- methylpyrrolidin-l-yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(4-Fluorphenyl)-4-methyl-2-(4-((S)-2-((R)-2-methylpyrrc>lidin-l- yl)propoxy)phenyl)-2H-chromen-6-ol; 2- (4-((S)-2-((R)-3-Fluoropyrrolidin-l-yl)propoxy)phenyl)-3-(3-hydroxyphenyl)-4-methyl-2H-chromen-6-ol; 3- (4-Hydroxyphenyl)-2-(4-((S)-2-((R)-3-methylpyrrolidin-l-yl)propoxy)phenyl)-4-(trifluormethyl)-2H-chromen-6-ol; 3-(3-Hydroxyphenyl)-2-(4-((S)-2-((R)-3-methylpyrrolidin-l- yl)propoxy)phenyl)-4-(trifluormethyl)-2H-chromen-6-ol; 3-(3-Hydroxy-4-(trifluormethyl)phenyl)-4-methyl-2-(4-((S)-2-((R)-3- methylpyrrolidin-l-yl)propoxy)phenyl)-2H-chromen-6-ol; 3-(4-Hydroxy-3-(trifluormethyl)phenyl)-4-methyl-2-(4-((S)-2-((R)-3- methylpyrrolidin-l-yl)propoxy)phenyl)-2H-chromen-6-ol; eller et farmaceutisk acceptabelt salt deraf.
10. Farmaceutisk sammensætning omfattende en forbindelse ifølge et hvilket som helst af kravene 1-9, eller et farmaceutisk acceptabelt salt deraf.
11. Den farmaceutiske sammensætning ifølge krav 10, hvor den farmaceutiske sammensætning er formuleret til intravenøs injektion, subkutan injektion, oral administration, eller topikal administration.
12. Den farmaceutiske sammensætning ifølge krav 10, hvor den farmaceutiske sammensætning er i form af en tablet, en pille, en kapsel, en væske, en suspension, en gel, en dispersion, en opløsning, en emulsion, en salve, eller en lotion.
13. Forbindelsen ifølge et hvilket som helst af kravene 1-9, eller et farmaceutisk acceptabelt salt deraf til anvendelse i behandlingen afen østrogenreceptor-afhængig eller østrogenreceptor-medieret sygdom eller tilstand hos pattedyr.
14. Forbindelsen til anvendelse ifølge krav 13, hvor den østrogen receptorafhængige eller østrogenreceptor-medierede sygdom eller tilstand er valgt fra kræft, central nervesystem (CNS) -defekter, kardiovaskulær system-defekter, hæmatologisk system-defekter, immun- og inflammationssygdomme, modtagelighed over for infektion, stofskiftedefekter, neurologiske defekter, psykiatriske defekter og forplantningsdefekter.
15. Forbindelsen til anvendelse ifølge krav 13, hvor den østrogen receptorafhængige eller østrogenreceptor-medierede sygdom eller tilstand er valgt fra knoglekræft, brystkræft, lungekræft, kolorektalkræft, endometrialkræft, prostatakræft, æggestokskræft, livmoderkræft, alkoholisme, migræne, aortaaneurisme, modtagelighed over for myokardieinfarkt, aortaklapsklerose, kardiovaskulær sygdom, kranspulsåresygdom, hypertension, dyb venetrombose, Graves sygdom, arthritis, multiple sklerose, cirrose, hepatitis B, kronisk leversygdom, knogledensitet, cholestase, hypospadi, fedme, osteoarthritis, osteopeni, osteoporose, Alzheimers sygdom, Parkinsons sygdom, migræne, svimmelhed, anorexia nervosa, forstyrrelser af opmærksomhed, aktivitet og impulsitivitet (ADHD), demens, klinisk depression, psykose, menarchealderen, endometriose, og infertilitet.
16. Forbindelsen ifølge et hvilket som helst af kravene 1-9, eller et farmaceutisk acceptabelt salt deraf, til anvendelse i behandlingen af kræft hos pattedyr.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35353110P | 2010-06-10 | 2010-06-10 | |
PCT/US2011/039669 WO2011156518A2 (en) | 2010-06-10 | 2011-06-08 | Estrogen receptor modulators and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
DK2580210T3 DK2580210T3 (da) | 2017-06-12 |
DK2580210T5 true DK2580210T5 (da) | 2017-06-19 |
Family
ID=45098650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11793115.4T DK2580210T5 (da) | 2010-06-10 | 2011-06-08 | Østrogenreceptormodulatorer og anvendelser deraf |
Country Status (24)
Country | Link |
---|---|
US (2) | US8703810B2 (da) |
EP (2) | EP3205648A1 (da) |
JP (3) | JP2013528223A (da) |
KR (1) | KR101698238B1 (da) |
CN (1) | CN102939287B (da) |
AU (1) | AU2011264858B2 (da) |
BR (1) | BR112012031464A2 (da) |
CA (1) | CA2800673A1 (da) |
CY (1) | CY1120450T1 (da) |
DK (1) | DK2580210T5 (da) |
EA (1) | EA022551B1 (da) |
ES (1) | ES2627692T3 (da) |
HR (1) | HRP20170786T1 (da) |
HU (1) | HUE033581T2 (da) |
IL (1) | IL223044B (da) |
LT (1) | LT2580210T (da) |
MX (1) | MX2012014431A (da) |
PL (1) | PL2580210T3 (da) |
PT (1) | PT2580210T (da) |
RS (1) | RS56042B1 (da) |
SG (1) | SG185637A1 (da) |
SI (1) | SI2580210T1 (da) |
WO (1) | WO2011156518A2 (da) |
ZA (1) | ZA201208603B (da) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3205648A1 (en) | 2010-06-10 | 2017-08-16 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
WO2013056178A2 (en) | 2011-10-14 | 2013-04-18 | Foundation Medicine, Inc. | Novel estrogen receptor mutations and uses thereof |
EA029559B1 (ru) | 2011-12-14 | 2018-04-30 | Серагон Фармасьютикалс, Инк. | Фторированные модуляторы рецепторов эстрогенов и их применение |
WO2013090921A1 (en) * | 2011-12-16 | 2013-06-20 | Olema Pharmaceuticals, Inc. | Novel benzopyran compounds, compositions and uses thereof |
WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
WO2014203129A1 (en) * | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
BR112015030595A2 (pt) | 2013-06-19 | 2017-07-25 | Seragon Pharmaceuticals Inc | moduladores de receptor de estrogênio de azetidina e usos dos mesmos |
PE20160157A1 (es) | 2013-06-19 | 2016-03-18 | Seragon Pharmaceuticals Inc | Moduladores de los receptores de estrogeno y sus usos |
WO2015136017A1 (en) | 2014-03-13 | 2015-09-17 | F. Hoffmann-La Roche Ag | Methods and compositions for modulating estrogen receptor mutants |
JP2017507964A (ja) | 2014-03-13 | 2017-03-23 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | エストロゲン受容体モジュレーターを用いた治療的組合せ |
KR102559719B1 (ko) | 2014-12-18 | 2023-07-26 | 에프. 호프만-라 로슈 아게 | 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도 |
US9845291B2 (en) | 2014-12-18 | 2017-12-19 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
CN107406433A (zh) * | 2014-12-18 | 2017-11-28 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的2,3‑二苯基色烯的衍生物 |
US10053451B2 (en) | 2015-05-26 | 2018-08-21 | Genentech, Inc. | Heterocyclic estrogen receptor modulators and uses thereof |
EP3331905B1 (en) | 2015-08-06 | 2022-10-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
PL3355884T3 (pl) | 2015-10-01 | 2021-11-29 | Olema Pharmaceuticals, Inc. | Tetrahydro-1H-pirydo[3,4-b]indolowe leki antyestrogenowe |
DK3368519T3 (da) * | 2015-10-27 | 2022-05-23 | Sun Pharma Advanced Res Co Ltd | Hidtil ukendte, heterocykliske antiøstrogener |
WO2017080338A1 (zh) | 2015-11-12 | 2017-05-18 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物、其制备方法及其在医药上的用途 |
MX2018007079A (es) | 2015-12-09 | 2018-11-12 | The Board Of Trustees Of Univ Of Illinois | Reguladores a la baja del receptor de estrogeno selectivo de benzotiofeno. |
CN113004273A (zh) * | 2016-02-05 | 2021-06-22 | 益方生物科技(上海)股份有限公司 | 选择性雌激素受体降解物及其用途 |
WO2017172957A1 (en) | 2016-04-01 | 2017-10-05 | Kalyra Pharmaceuticals, Inc. | Estrogen receptor modulators |
TW201803870A (zh) | 2016-04-20 | 2018-02-01 | 阿斯特捷利康公司 | 化學化合物 |
CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
RU2019102647A (ru) | 2016-07-01 | 2020-08-03 | Г1 Терапьютикс, Инк. | Антипролиферационные средства на основе пиримидина |
WO2018019793A1 (en) | 2016-07-25 | 2018-02-01 | Astrazeneca Ab | N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
HUE057524T2 (hu) | 2016-10-24 | 2022-05-28 | Astrazeneca Ab | 6,7,8,9-Tetrahidro-3H-pirazolo[4,3-f]izokinolin-származékok rák kezelésében való alkalmazásra |
MX2019007748A (es) * | 2017-01-05 | 2019-09-09 | Radius Pharmaceuticals Inc | Formas polimorficas de rad1901-2hcl. |
BR112019013814A2 (pt) | 2017-01-06 | 2020-01-21 | G1 Therapeutics Inc | método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit. |
LT3494116T (lt) | 2017-01-30 | 2020-01-10 | Astrazeneca Ab | Estrogeno receptorių moduliatoriai |
CN111386263A (zh) | 2017-02-08 | 2020-07-07 | 达纳-法伯癌症研究所有限公司 | 调节嵌合抗原受体 |
JP2020507566A (ja) | 2017-02-10 | 2020-03-12 | ジー1 セラピューティクス, インコーポレイテッド | ベンゾチオフェンエストロゲン受容体モジュレーター |
WO2019006393A1 (en) | 2017-06-29 | 2019-01-03 | G1 Therapeutics, Inc. | MORPHIC FORMS OF GIT38 AND METHODS OF MAKING SAME |
WO2019057201A1 (zh) * | 2017-09-25 | 2019-03-28 | 罗欣生物科技(上海)有限公司 | 一种雌激素受体抑制剂的晶型及其制备方法 |
US11624095B2 (en) | 2017-09-27 | 2023-04-11 | Case Western Reserve University | Method of quantifying HIV reservoirs by induced transcription based sequencing |
CA3079407A1 (en) | 2017-10-18 | 2019-04-25 | Novartis Ag | Compositions and methods for selective protein degradation |
CA3081602A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
MX2020011531A (es) | 2018-06-21 | 2021-03-25 | Hoffmann La Roche | Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil )azetidin-3 il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3 ,4-b]indol-2-il)-2,2 difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso. |
WO2020010216A1 (en) | 2018-07-04 | 2020-01-09 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad 1901-2hcl |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
CN108911967A (zh) * | 2018-08-03 | 2018-11-30 | 上海华堇生物技术有限责任公司 | 2,5–二甲氧基苯甲酰氯的制备方法 |
CA3109090A1 (en) | 2018-08-17 | 2020-02-20 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for the treatment of breast cancer |
WO2020051235A1 (en) | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
US20240245670A1 (en) | 2018-12-20 | 2024-07-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
BR112021015672A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos |
EP3924054A1 (en) | 2019-02-15 | 2021-12-22 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
JP2022533400A (ja) | 2019-05-20 | 2022-07-22 | ノバルティス アーゲー | Mcl-1阻害剤抗体-薬物コンジュゲートおよび使用方法 |
JP2022534037A (ja) | 2019-05-24 | 2022-07-27 | 浙江海正薬業股▲ふん▼有限公司 | アクリル酸系誘導体の結晶形およびその調製方法及び用途 |
KR20220046586A (ko) | 2019-07-22 | 2022-04-14 | 썬 파마 어드밴스트 리서치 컴패니 리미티드 | 선택적 에스트로겐 수용체 분해제 |
WO2021026153A1 (en) | 2019-08-06 | 2021-02-11 | Recurium Ip Holdings, Llc | Estrogen receptor modulators for treating mutants |
WO2021123902A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
CN118344370A (zh) | 2019-12-20 | 2024-07-16 | C4医药公司 | 用于egfr降解的异吲哚啉酮和吲唑化合物 |
MX2022015852A (es) | 2020-06-23 | 2023-01-24 | Novartis Ag | Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CN117136076A (zh) | 2020-11-24 | 2023-11-28 | 诺华股份有限公司 | Mcl-1抑制剂抗体药物缀合物和使用方法 |
CR20230283A (es) | 2020-11-24 | 2023-07-27 | Novartis Ag | Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos |
WO2022140744A1 (en) | 2020-12-23 | 2022-06-30 | Recurium Ip Holdings, Llc | Estrogen receptor modulators |
US20240182464A1 (en) | 2021-02-02 | 2024-06-06 | Les Laboratoirens Serviece | Selective bcl-xl protac compounds and methods of use |
CN115073273A (zh) * | 2021-03-15 | 2022-09-20 | 中国医学科学院药物研究所 | 二苯烷类化合物及其制备方法、药物组合物和用途 |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2023225336A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
WO2024097989A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
WO2024097980A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein inhibitors |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US5011692A (en) | 1985-12-28 | 1991-04-30 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
US5686465A (en) | 1988-10-31 | 1997-11-11 | Endorecherche Inc. | Sex steroid activity inhibitors |
US5395842A (en) | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
US5254568A (en) | 1990-08-09 | 1993-10-19 | Council Of Scientific & Industrial Research | Benzopyrans as antiestrogenic agents |
EP0470310B1 (en) * | 1990-08-09 | 1995-11-29 | Council of Scientific and Industrial Research | Novel benzopyrans and process for their production |
US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
ATE157869T1 (de) | 1993-06-24 | 1997-09-15 | Lilly Co Eli | Antiöstrogene 2-phenyl-3-aroylbenzothiophene als hypoglykämische mittel |
US5446061A (en) * | 1993-11-05 | 1995-08-29 | Eli Lilly And Company | Methods for lowering serum cholesterol |
US5407947A (en) * | 1993-11-05 | 1995-04-18 | Eli Lilly And Company | Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans |
US5389646A (en) | 1993-12-30 | 1995-02-14 | Zymogenetics, Inc. | Methods for treatment and prevention of bone loss using 2,3-benzopyrans |
US5416098A (en) | 1993-12-30 | 1995-05-16 | Zymogenetics, Inc. | Method for treating dermatitis and related conditions |
US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
NZ272608A (en) | 1994-07-22 | 2000-05-26 | Lilly Co Eli | Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts |
US5446071A (en) | 1994-11-18 | 1995-08-29 | Eli Lilly And Company | Methods for lowering serum cholesterol |
US5637598A (en) | 1994-11-18 | 1997-06-10 | Eli Lilly And Company | Methods of inhibiting bone loss |
US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US5980938A (en) | 1996-07-15 | 1999-11-09 | Eli Lilly And Company | Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1) |
JP2001502708A (ja) | 1996-10-28 | 2001-02-27 | ノボ ノルディスク アクティーゼルスカブ | エストロゲン関連の疾患または症候群の予防または治療に有用な新規なシス―3,4―クロマン誘導体 |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
WO1999002512A1 (en) | 1997-07-09 | 1999-01-21 | Novo Nordisk A/S | Dl-2,3-diaryl-2h-1-benzopyrans |
AU8102498A (en) | 1997-07-09 | 1999-02-08 | Central Drug Research Institute | Preparation of diaryl-benzopyrans |
WO1999008682A1 (en) | 1997-08-15 | 1999-02-25 | Duke University | A method of preventing or treating estrogen-dependent diseases and disorders |
US6326392B1 (en) | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
UA68365C2 (en) | 1997-11-06 | 2004-08-16 | Wyeth Corp | Peroral contraception by combination of anti-estrogen and progestin |
EP1068529A4 (en) | 1998-03-30 | 2004-08-04 | Univ California | METHODS AND COMPOUNDS FOR MODULATING THE BINDING OF A COACTIVATOR TO NUCLEAR RECEPTORS |
JP2002516983A (ja) | 1998-03-30 | 2002-06-11 | ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア | 核受容体活性を調節するための方法及び化合物 |
US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US7005428B1 (en) | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
EP1104414B1 (en) | 1998-08-14 | 2003-02-12 | Schering Corporation | Enantioselective synthesis |
US6262270B1 (en) * | 1998-08-14 | 2001-07-17 | Schering Corporation | Enantioselective synthesis |
AU2156800A (en) | 1998-12-18 | 2000-07-12 | Schering Corporation | Oral antiestrogen pharmaceutical composition |
US6638727B1 (en) | 1999-01-26 | 2003-10-28 | Cytyc Health Corporation | Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
DE19916419B4 (de) | 1999-04-08 | 2005-06-16 | Schering Ag | Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose |
KR101141763B1 (ko) | 1999-07-06 | 2012-05-08 | 앙도르쉐르슈 인코포레이티드 | 체중 증가의 치료 및/또는 억제에 사용하는 약학 조성물 |
AU7896100A (en) | 1999-10-14 | 2001-04-23 | Endorecherche Inc. | Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance |
GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
CO5271709A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos |
CO5271696A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para reducir la morbilidad y el riesgo de mortalidad |
CO5271697A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
CO5251465A1 (es) | 2000-01-26 | 2003-02-28 | Pfizer Prod Inc | Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol |
CA2395730A1 (en) | 2000-01-28 | 2001-08-02 | Endorecherche, Inc. | Selective estrogen receptor modulators in combination with estrogens |
WO2001063292A2 (en) | 2000-02-22 | 2001-08-30 | Board Of Regents, The University Of Texas System | Compositions and methods of use of het, a novel modulator of estrogen action |
DE10013782A1 (de) | 2000-03-15 | 2001-10-18 | Schering Ag | 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
US6528681B2 (en) | 2000-04-05 | 2003-03-04 | Bristol-Meyers Squibb Pharma Company | Halogenated triphenylethylene derivatives as selective estrogen receptor modulators |
US20020013327A1 (en) | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
US7863011B2 (en) | 2000-05-10 | 2011-01-04 | Signe Biopharma, Inc. | Screening method for predicting susceptibility to breast cancer |
US8119138B2 (en) | 2000-05-10 | 2012-02-21 | Signe Biopharma Inc. | Anti-estrogen and immune modulator combinations for treating breast cancer |
EP1177787A3 (en) | 2000-07-28 | 2003-09-10 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating cataracts |
AU2001283139A1 (en) | 2000-08-11 | 2002-02-25 | Wyeth | Method of treating estrogen receptor positive carcinoma |
US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
CA2419590A1 (en) | 2000-09-08 | 2002-03-14 | Pharmacia Italia S.P.A. | Exemestane as chemopreventing agent |
EP1192945A3 (en) | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
IL155237A0 (en) | 2000-10-06 | 2003-11-23 | Biomedicines Inc | Combination therapy for the treatment of estrogen-sensitive disease |
IL145838A (en) | 2000-10-16 | 2008-11-03 | Pfizer Prod Inc | Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis |
CA2424726A1 (en) | 2000-10-19 | 2002-04-25 | Merck & Co., Inc. | Estrogen receptor modulators |
EE200300153A (et) | 2000-10-19 | 2003-06-16 | Merck & Co., Inc. | Östrogeeni retseptori modulaatorid, farmatseutiline kompositsioon ja selle valmistamismeetod |
US6750213B2 (en) | 2000-10-19 | 2004-06-15 | Merck & Co., Inc. | Estrogen receptor modulators |
AU781168B2 (en) | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
MXPA03006607A (es) | 2001-01-26 | 2003-09-22 | Upjohn Co | Metodo combinado para tratar trastornos dependientes de hormonas. |
US20040082557A1 (en) | 2001-01-26 | 2004-04-29 | Wajszczuk Charles Paul | Methods for treating estrogen-dependent disorders |
GB2374412A (en) | 2001-04-11 | 2002-10-16 | Karobio Ab | Hypertension treatment and assay |
PL374215A1 (en) | 2001-08-11 | 2005-10-03 | Bristol-Myers Squibb Pharma Company | Selective estrogen receptor modulators |
CA2459943A1 (en) | 2001-09-21 | 2003-04-03 | Merck & Co., Inc. | Androstanes as androgen receptor modulators |
JP4490689B2 (ja) | 2001-10-03 | 2010-06-30 | メルク・シャープ・エンド・ドーム・コーポレイション | アンドロゲン受容体調節剤としてのアンドロスタン17β−カルボキサミド類 |
NZ532064A (en) | 2001-10-10 | 2006-04-28 | Pharmacia Italia Spa | Methods for preventing and treating bone loss with steroid compounds |
JP2005509629A (ja) | 2001-10-19 | 2005-04-14 | メルク エンド カムパニー インコーポレーテッド | アンドロゲン受容体モジュレーターおよびその使用方法 |
US7105679B2 (en) * | 2001-12-19 | 2006-09-12 | Kanojia Ramesh M | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
JP2005513133A (ja) * | 2001-12-19 | 2005-05-12 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | エストロゲン受容体調節剤としての四環状複素化合物 |
WO2003063859A1 (en) | 2002-01-14 | 2003-08-07 | Nordic Bioscience A/S | Suppression of cartilage degradation via the estrogen receptor |
WO2003070253A1 (en) | 2002-02-21 | 2003-08-28 | Pantarhei Bioscience B.V. | Estrogenic component for treating decreased libido in women |
BR0308355A (pt) | 2002-03-13 | 2005-01-25 | Merck & Co Inc | Composto ou um sal farmaceuticamente aceitável ou um seu enanciÈmero, métodos para modular uma função mediada pelo receptor de androgênio em um mamìfero em necessidade de tal modulação, para ativar a função do receptor de androgênio em um mamìfero em necessidade de tal ativação, para tratar uma condição em um mamìfero, e para tratar osteoporose em um mamìfero em sua necessidade, composição farmacêutica, métodos para aumentar a densidade mineral óssea em um mamìfero em necessidade disto, para reduzir o risco de fraturas vertebrais ou não vertebrais em um mamìfero em necessidade disto, e para produzir um marcador de modificação óssea em um mamìfero em necessidade disto, processo para produzir uma composição farmacêutica, e, método para tratar ou prevenir uma condição artrìtica em um mamìfero em necessidade disto |
JP2005519610A (ja) | 2002-03-13 | 2005-07-07 | エフ.ホフマン−ラ ロシュ アーゲー | 薬剤感受性規定因子の選択方法および選択された因子を用いた薬剤感受性の予測方法 |
US20030225132A1 (en) | 2002-04-11 | 2003-12-04 | Dininno Frank P. | Estrogen receptor modulators |
SI1501819T1 (sl) * | 2002-04-24 | 2011-01-31 | Merck Sharp & Dohme | Modulatorji estrogen receptorjev |
AU2003223754B2 (en) | 2002-04-30 | 2007-08-16 | Merck Sharp & Dohme Corp. | 4-azasteroid derivatives as androgen receptor modulators |
AU2003247608A1 (en) | 2002-06-25 | 2004-01-06 | Wyeth | Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions |
MXPA04012419A (es) | 2002-06-25 | 2005-04-19 | Wyeth Corp | Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con la hormona. |
AU2003286757B2 (en) | 2002-11-01 | 2009-06-04 | Merck Sharp & Dohme Corp. | Carbonylamino-benzimidazole derivatives as androgen receptor modulators |
WO2004091488A2 (en) * | 2003-04-14 | 2004-10-28 | Merck & Co., Inc. | Estrogen receptor modulators |
EP1622567B1 (en) | 2003-05-07 | 2013-07-24 | Merck Sharp & Dohme Corp. | Androgen receptor modulators and methods of use thereof |
CA2524610C (en) | 2003-05-07 | 2014-03-25 | Osteologix A/S | Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions |
US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
AU2004259664B2 (en) | 2003-06-30 | 2009-05-28 | Merck Sharp & Dohme Corp. | 17-acetamido-4-azasteroid derivatives as androgen receptor modulators |
JP2007521297A (ja) | 2003-06-30 | 2007-08-02 | メルク エンド カムパニー インコーポレーテッド | アンドロゲン受容体モジュレータとしての17−アセトアミド−4−アザステロイド誘導体 |
CA2530182A1 (en) | 2003-06-30 | 2005-01-20 | Merck & Co., Inc. | 17-acetamido-4-azasteroid derivatives as androgen receptor modulators |
JP2007521293A (ja) | 2003-06-30 | 2007-08-02 | メルク エンド カムパニー インコーポレーテッド | アンドロゲン受容体モジュレータとしての17−アセトアミド−4−アザステロイド誘導体 |
CA2537660A1 (en) | 2003-09-10 | 2005-03-24 | Merck & Co., Inc. | 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators |
WO2005025579A1 (en) | 2003-09-10 | 2005-03-24 | Merck & Co., Inc. | 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators |
US7442833B2 (en) | 2003-10-08 | 2008-10-28 | Smithkline Beecham Corporation | Triphenylethylene compounds as selective estrogen receptor modulators |
EP1696925A4 (en) | 2003-10-31 | 2009-11-18 | Merck & Co Inc | 21-Heterocyclic 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS |
WO2005073190A1 (en) | 2004-01-29 | 2005-08-11 | Eli Lilly And Company | Selective estrogen receptor modulators |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
EP1758653A2 (en) | 2004-06-17 | 2007-03-07 | Osteologix A/S | Treatments comprising strontium for rheumatic and arthritic diseases and pain |
WO2005123130A2 (en) | 2004-06-17 | 2005-12-29 | Osteologix A/S | Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor |
MX2007002606A (es) | 2004-09-03 | 2007-05-15 | Hormos Medical Ltd | Uso de un modulador del receptor selectivo a estrogeno para la elaboracion de una preparacion farmaceutica para uso en un metodo para el tratamiento o prevencion de la deficiencia de androgenos. |
HUE025651T2 (en) | 2004-10-20 | 2016-04-28 | Endorecherche Inc | Sex Steroid precursor in combination with a selective estrogen receptor modulator to prevent and treat vaginal atrophy in postmenopausal women |
WO2006084937A1 (en) | 2005-02-14 | 2006-08-17 | Leskelae Hannu-Ville | Method for diagnosing and treating women with increased response to hormonal replacement therapy |
US20070078114A1 (en) | 2005-09-02 | 2007-04-05 | Myriad Genetics, Incorporated | Combination therapy for alzheimer's disease and other diseases |
WO2007098090A2 (en) | 2006-02-17 | 2007-08-30 | Novacea, Inc. | Treatment of hyperproliferative diseases with n-oxides of estrogen receptor modulators |
US20080268041A1 (en) | 2007-04-23 | 2008-10-30 | Jens Hoffmann | Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases |
DE102007026877A1 (de) | 2007-06-08 | 2008-12-11 | Bayer Schering Pharma Aktiengesellschaft | Verwendung des Fibroblastenwachstumsfaktors 7 (Fgf7) und des Rezeptors Fgfr2b als Biomarker |
US20110104121A1 (en) | 2008-05-21 | 2011-05-05 | Wira Charles R | Female Reproductive Tract and Anal Prophylaxes |
WO2010107474A1 (en) | 2009-03-16 | 2010-09-23 | The Research Foundation Of State University Of New York | Antiestrogens for breast cancer therapy |
US20100317635A1 (en) | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
EP3205648A1 (en) | 2010-06-10 | 2017-08-16 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
DE102010030538A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Schering Pharma Aktiengesellschaft | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
GB2483736B (en) * | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
AU2011347718B2 (en) | 2010-12-24 | 2016-06-23 | Msd Oss B.V. | N-substituted azetidine derivatives |
EA029559B1 (ru) | 2011-12-14 | 2018-04-30 | Серагон Фармасьютикалс, Инк. | Фторированные модуляторы рецепторов эстрогенов и их применение |
WO2013090921A1 (en) | 2011-12-16 | 2013-06-20 | Olema Pharmaceuticals, Inc. | Novel benzopyran compounds, compositions and uses thereof |
-
2011
- 2011-06-08 EP EP17157571.5A patent/EP3205648A1/en not_active Withdrawn
- 2011-06-08 JP JP2013514346A patent/JP2013528223A/ja active Pending
- 2011-06-08 LT LTEP11793115.4T patent/LT2580210T/lt unknown
- 2011-06-08 WO PCT/US2011/039669 patent/WO2011156518A2/en active Application Filing
- 2011-06-08 US US13/702,394 patent/US8703810B2/en active Active
- 2011-06-08 MX MX2012014431A patent/MX2012014431A/es active IP Right Grant
- 2011-06-08 AU AU2011264858A patent/AU2011264858B2/en not_active Ceased
- 2011-06-08 DK DK11793115.4T patent/DK2580210T5/da active
- 2011-06-08 KR KR1020137000592A patent/KR101698238B1/ko active IP Right Grant
- 2011-06-08 CN CN201180028527.XA patent/CN102939287B/zh active Active
- 2011-06-08 CA CA2800673A patent/CA2800673A1/en not_active Abandoned
- 2011-06-08 EP EP11793115.4A patent/EP2580210B1/en active Active
- 2011-06-08 EA EA201270815A patent/EA022551B1/ru not_active IP Right Cessation
- 2011-06-08 PT PT117931154T patent/PT2580210T/pt unknown
- 2011-06-08 SI SI201131201T patent/SI2580210T1/sl unknown
- 2011-06-08 PL PL11793115T patent/PL2580210T3/pl unknown
- 2011-06-08 RS RS20170530A patent/RS56042B1/sr unknown
- 2011-06-08 SG SG2012084737A patent/SG185637A1/en unknown
- 2011-06-08 ES ES11793115.4T patent/ES2627692T3/es active Active
- 2011-06-08 BR BR112012031464-5A patent/BR112012031464A2/pt not_active IP Right Cessation
- 2011-06-08 HU HUE11793115A patent/HUE033581T2/hu unknown
-
2012
- 2012-11-15 IL IL223044A patent/IL223044B/en active IP Right Grant
- 2012-11-15 ZA ZA2012/08603A patent/ZA201208603B/en unknown
-
2013
- 2013-12-20 US US14/137,394 patent/US9078871B2/en active Active
-
2016
- 2016-07-28 JP JP2016149008A patent/JP6465840B2/ja active Active
-
2017
- 2017-05-26 HR HRP20170786TT patent/HRP20170786T1/hr unknown
- 2017-05-31 CY CY20171100559T patent/CY1120450T1/el unknown
-
2018
- 2018-08-15 JP JP2018153006A patent/JP2018203751A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2580210T5 (da) | Østrogenreceptormodulatorer og anvendelser deraf | |
US8853423B2 (en) | Indane estrogen receptor modulators and uses thereof | |
EP2791133B1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
DK2735562T3 (da) | Østrogenreceptormodulatorer og anvendelser deraf | |
EP3303326B1 (en) | Heterocyclic estrogen receptor modulators and uses thereof | |
AU2014281511A1 (en) | Estrogen receptor modulator and uses thereof |